Design and Discovery of New Collagen V-Derived FGF2-Blocking Natural Peptides Inhibiting Lung Squamous Cell Carcinoma in Vitro and in Vivo.
Keli Kuang,Xiang Chen,Maolin Wang,Weijing Han,Xue Qiu,Taoli Jin,Rong Xu,Bing Yuan,Meiqi Qian,Chunyan Li,Run Xiang,Fei Li,Shuwen Zhang,Zi Yang,Junrong Du,Dapeng Li,Chun Zhang,Qiantao Wang,Tao Jia
DOI: https://doi.org/10.1021/acs.jmedchem.4c00654
IF: 8.039
2024-01-01
Journal of Medicinal Chemistry
Abstract:Aberrant FGF2/FGFR signaling is implicated in lung squamous cell carcinoma (LSCC), posing treatment challenges due to the lack of targeted therapeutic options. Designing drugs that block FGF2 signaling presents a promising strategy different from traditional kinase inhibitors. We previously reported a ColVα1-derived fragment, HEPV (127AA), that inhibits FGF2-induced angiogenesis. However, its large size may limit therapeutic application. This study combines rational peptide design, molecular dynamics simulations, knowledge-based prediction, and GUV and FRET assays to identify smaller peptides with FGF2-blocking properties. We synthesized two novel peptides, HBS-P1 (45AA) and HBS-P2 (66AA), that retained the heparin-binding site. Both peptides demonstrated anti-LSCC and antiangiogenesis properties in cell viability and microvessel network induction assays. In two LSCC subcutaneous models, HBS-P1, with its affinity for FGF2 and enhanced penetration ability, demonstrated substantial therapeutic potential without apparent toxicities. Our study provides the first evidence supporting the development of collagen V-derived natural peptides as FGF2-blocking agents for LSCC treatment.